

# TABLE OF CONTENTS

## Endocrinology and Rheumatology Care I . . . . 1

Endocrinology and Rheumatology Care I Panel . . . . .	3
---	---

## Cardiorenal Outcomes in Type 2 Diabetes

*By Kira Harris, Pharm.D., FCCP, BCPS, CDCES, CPP; and Kimberly Lovin Nealy, Pharm.D., BCPS, CDCES, CPP*

Introduction . . . . .	7
CV Outcomes . . . . .	8
Renal Outcomes . . . . .	14
Discussion on Place in Therapy/Treatment Algorithms . . . . .	20
Conclusion . . . . .	22
References . . . . .	22
Self-Assessment Questions . . . . .	25

## Other Classifications of Diabetes

*By Lalita Prasad-Reddy, Pharm.D., MS, BCPS, BCACP, CDCES; and Diana Isaacs, Pharm.D., FADCES, FCCP, BCPS, BCACP, BC-ADM, CDCES*

Introduction . . . . .	29
Clinical Tests to Differentiate Diabetes . . . . .	30
Latent Autoimmune Diabetes in Adults . . . . .	30
Ketosis-Prone Diabetes . . . . .	34
Monogenic Diabetes . . . . .	34
Diabetes of the Exocrine Pancreas . . . . .	36
Drug-Induced Diabetes . . . . .	37
Future Directions and Research . . . . .	42
Conclusion . . . . .	43
References . . . . .	43
Self-Assessment Questions . . . . .	47

## Endocrinology and Rheumatology Care II . . 51

Endocrinology and Rheumatology Care II Panel . . . . .	53
--	----

## Hyperuricemia and Gout

*By Youssef M. Roman, Pharm.D., Ph.D.; and Nehal R. Shah, M.D.*

Epidemiology of Hyperuricemia and Gout . . . . .	57
Gout Diagnosis . . . . .	63
Pharmacotherapy Management of Gout Flares . . . . .	63
Considerations for Initiating ULTs and Gout Flare Prophylaxis . . . . .	67
Pharmacotherapy for the Management of Chronic Gout . . . . .	67
Cardiovascular Drugs with Uricosuric Properties . . . . .	72
Gout and Quality of Life . . . . .	73
Role of Lifestyle Modifications in Gout Management . . . . .	73
Challenges and Opportunities in Gout Management . . . . .	74
Conclusion . . . . .	75
References . . . . .	76
Self-Assessment Questions . . . . .	79

## Osteoporosis

*By Veronica Vernon, Pharm.D., BCPS, BCACP, NCMP*

Introduction . . . . .	83
Diagnostic Evaluation . . . . .	84
Drug-Induced Osteoporosis . . . . .	87
Prevention . . . . .	88
Treatment Approaches . . . . .	88
Pharmacotherapy for Osteoporosis . . . . .	91
Monitoring Values . . . . .	96
Pharmacists' Role . . . . .	97
Conclusion . . . . .	97
References . . . . .	98
Self-Assessment Questions . . . . .	101

## Biosimilars and Biologics in Rheumatology

*By Jeannie Hong, Pharm.D., BCPS; and Lanh Dang, Pharm.D., BCACP*

Introduction . . . . .	105
Biologic Medications Used in Rheumatology . . . . .	110
Biosimilars Used in Rheumatology . . . . .	118
Hot Topics with Biosimilars . . . . .	119
Role of the Pharmacist . . . . .	119
Conclusion . . . . .	120
References . . . . .	120
Self-Assessment Questions . . . . .	124

## Endocrinology and Rheumatology Care III .129

Endocrinology and Rheumatology Care III Panel . . . . .	131
---	-----

## Interactive Case: REMS in Rheumatology

*By Katharine McCarthy, Pharm.D., BCACP*

Interactive Case: REMS in Rheumatology . . . . .	135
Hyperlink to activity . . . . .	136
Self-Assessment Questions . . . . .	137

## Interactive Case: Diabetes Technology

*By Rick Hess, Pharm.D., BCACP, CDCES, BC-ADM*

Interactive Case: Diabetes Technology . . . . .	141
Hyperlink to activity . . . . .	142
Self-Assessment Questions . . . . .	145

## Interactive Case: Obesity

*By Pamela L. Stamm, Pharm.D., FASHP, BCPS, BCACP, CDCES*

Interactive Case: Obesity . . . . .	149
Hyperlink to activity . . . . .	150
Self-Assessment Questions . . . . .	154